BioAge Labs R&D Day and NLRP3 Asset Analysis

Goldman Sachs analyzes BioAge Labs' R&D day, emphasizing the mechanistic rationale for BGE-102 in cardiovascular and ocular indications and its strong Phase 1 inflammation reduction data.

Key Takeaways

• 1.BioAge Labs (BIOA) showcased the structural differentiation of BGE-102, an oral NLRP3 inhibitor, highlighting its unique binding site and ability to target all states of the NLRP3 protein.
• 2.Phase 1 data in obese patients demonstrated a significant ~86% reduction in hsCRP, providing high confidence for upcoming Phase 2 clinical readouts.
• 3.The company has a significant cash runway through 2029 following a $132mn follow-on offering in January 2026.

Table of Contents

• Takeaways from the R&D Day
• 1Q26 EPS vs. GSe; Cash runway through 2029
• Valuation and Risks
• Disclosure Appendix

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial